Dr. Kim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir Rd NW
Washington, DC 20007Phone+1 202-444-2223Fax+1 202-444-9429
Education & Training
National Institutes of Health Clinical CenterFellowship, Medical Oncology, 2014 - 2017
OtherClass of 2007
University of MinnesotaResidency, Internal Medicine
Certifications & Licensure
DC State Medical License 2017 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy Start of enrollment: 2020 Apr 16
- A Study to Investigate LYL797 in Adults With Solid Tumors Start of enrollment: 2022 Mar 29
Roles: Contact
- MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer Start of enrollment: 2024 Apr 15
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 18 citationsSafety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in Pe...Talal El Zarif, Amin H Nassar, Elio Adib, Bailey G Fitzgerald, Jiaming Huang
Journal of Clinical Oncology. 2023-07-20 - 1 citationsReal-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, Amin H Nassar, Elio Adib
Clinical Lymphoma, Myeloma & Leukemia. 2024-08-01 - 29 citationsImmune checkpoint inhibitor use and tuberculosis: a systematic review of the literature.Jacob Zaemes, Chul Kim
European Journal of Cancer. 2020-06-01
Press Mentions
Chemo-IO over IO Alone in Patients with Advanced NSCLCJuly 13th, 2021- Genomic Test in Lung Cancer: Waiting Is the Hardest PartJuly 6th, 2021
- What Did We Learn from IMpower010 in Resectable NSCLC?June 22nd, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
